Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain Patient Care Online
Long-Term Data on Relugolix Combination Therapy for Endometriosis Pain Contemporary OB/GYN
Endometriosis is a prevalent gynecological disorder characterized by ectopic growth of endometrial-like tissue, often causing chronic pain, infertility, and systemic inflammation. Accurate detection and complete surgical resection remain challenging because …
Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …
In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …
Herlyn-Werner-Wunderlich syndrome, also referred to as obstructed hemivagina with ipsilateral renal agenesis (OHVIRA) is a rare congenital urogenital anomaly resulting from abnormal development of the Müllerian and Wolffian ducts, classically …
Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …
Endometriosis affects ∼10% of women of reproductive age. Emerging evidence suggests a link between endometriosis and systemic inflammation, potentially increasing the risk of venous thromboembolism (VTE), yet data on the …